Our technology combines optimized semiconductor manufacturing technique with unique biomediator preparation to achieve the first reliable POC biosensing platform. Sensors developed according to this method possess reproducibility, accuracy, and stability that meet POC. Our sensors are portable, require low sample volume, do not require sample processing, and are extremely suitable for use in POC settings. They can also be integrated into IoT systems to aide in rapid decision making, and can be mass produced. Overall, we are the first to achieve accessible, reliable detection at the POC.

1.Our technology achieves accurate detection while solving the problem of high noise and inconsistency, resulting in the first biosensor that meets requirements for POC testing.
2.Other biosensors are specific to single target and take 4-6 months to develop; our biomediator is modular, allowing for development of new sensors in 1 week that can target protein, DNA/RNA and compounds.
3.Our sensors require low sample volume (10 μl) and do not require sample processing. They can be integrated into IoT systems for fast communication, and are much more accessible in POC settings than other devices.

Initial mass production trials yielded 30,000 biochips/month with a CV of <5％, meeting POC standards. When compared with global detection standard methods (ELISA/PCR), our technology is much faster (5 min vs 30 min) and more accessible (portable, no sample processing). The electrochemical biosensor market has estimated value of 23.7 billion USD; with our technological breakthroughs, we plan to broaden the range of POC targets to detect analytes such as cTnI and COVID-19 virus that currently cannot be detected at the POC.

線上展網址：
https://tievirtual.twtm.com.tw/iframe/092d8287-4585-4d63-b12b-bb5d33bf25ff?group=23bfb1fa-dd5b-4836-81a1-4a1809b1bae5&lang=en